Sunshine Biopharma (SBFM) Short term Debt (2018 - 2019)
Sunshine Biopharma (SBFM) reported Short term Debt of $27541.0 for Q3 2019, down 1.18% quarter-over-quarter from $27869.0 in Q2 2019.
Sunshine Biopharma (SBFM) Short term Debt (2018 - 2019) Analysis & Trends
Sunshine Biopharma has reported Short term Debt for 2 years, with the latest figure at $27541.0 in Q3 2019.
- For the quarter ending Q3 2019, Short term Debt changed N/A year-over-year to $27541.0; the trailing twelve-month figure through Sep 2019 stood at $27541.0 (changed N/A YoY), and the FY2018 full-year result was $20871.0, changed N/A from the prior year.
- Short term Debt for Q3 2019 stood at $27541.0, down from $27869.0 in the prior quarter.
- The five-year high for Short term Debt was $59558.0 in Q1 2019, with the low at $20871.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Sunshine Biopharma | 10.94 Mn | 4.03 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 27,541.00 |
| Jun 30, 2019 | 27,869.00 |
| Mar 31, 2019 | 59,558.00 |
| Dec 31, 2018 | 20,871.00 |